Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5633681 | 0.88 | SMN1; SMN2 (0.60) | SMN1; SMN2MAPK1MAPTRAB9AHCRTR1 | |
| SCHEMBL20579804 | 0.86 | SMN1; SMN2 (0.78) | SMN1; SMN2MAPK1MAPTRAB9AHCRTR1 | |
| SCHEMBL7499292 | 0.85 | SMN1; SMN2 (0.76) | SMN1; SMN2MAPK1MAPTRAB9AHCRTR1 | |
| SCHEMBL17018450 | 0.84 | SMN1; SMN2 (0.74) | SMN1; SMN2MAPK1MAPTRAB9AHCRTR1 | |
| SCHEMBL9286867 | 0.81 | ALDH1A1 (0.54) | SMN1; SMN2MAPK1MAPTRAB9AHCRTR1 | |
| SCHEMBL10710957 | 0.81 | SMN1; SMN2 (0.69) | SMN1; SMN2MAPK1MAPTRAB9AHCRTR1 | |
| SCHEMBL10646189 | 0.79 | SMN1; SMN2 (0.66) | SMN1; SMN2MAPK1MAPTRAB9AHCRTR1 | |
| SCHEMBL10646063 | 0.79 | SMN1; SMN2 (0.66) | SMN1; SMN2MAPK1MAPTRAB9AHCRTR1 | |
| SCHEMBL15631933 | 0.78 | SMN1; SMN2 (0.65) | SMN1; SMN2MAPK1MAPTRAB9AHCRTR1 | |
| SCHEMBL15663664 | 0.78 | SMN1; SMN2 (0.54) | SMN1; SMN2MAPK1MAPTRAB9AHCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771360-B2 | Cyano-substituted imidazo[1,2-A]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-26 | — | — | US | disclosed |
| US-9771360-B2 | Cyano-substituted imidazo[1,2-A]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-26 | — | — | US | disclosed |
| US-9771360-B2 | Cyano-substituted imidazo[1,2-A]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-26 | — | — | US | disclosed |
| US-20170217954-A1 | CYANO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-03 | — | — | US | disclosed |
| US-20170217954-A1 | CYANO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-03 | — | — | US | disclosed |
| US-20170217954-A1 | CYANO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-03 | — | — | US | disclosed |
| EP-2914596-B1 | HYDROXY SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE CARBOXAMIDES AND THEIR USE AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE | Bayer Pharma AG (DE) | 2017-06-21 | — | — | EP | disclosed |
| EP-2914596-B1 | HYDROXY SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE CARBOXAMIDES AND THEIR USE AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE | Bayer Pharma AG (DE) | 2017-06-21 | — | — | EP | disclosed |
| US-20170057954-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-02 | — | — | US | disclosed |
| US-20170057954-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-02 | — | — | US | disclosed |
| WO-2014068104-A1 | HYDROXY-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE AS SOLUBLE GUANYLATE CYCLASE STIMULANTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | WO | disclosed |
| US-20140128424-A1 | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
| US-20140128424-A1 | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
| US-20140128386-A1 | Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
| US-20140128386-A1 | Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
| US-20140128424-A1 | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
| EP-0971920-B1 | COMPOUNDS FOR INHIBITION OF GASTRIC ACID SECRETION | ASTRAZENECA AB (SE) | 2002-06-05 | — | — | EP | disclosed |
| US-6265415-B1 | ANTIULCER AGENT | ASTRAZENECA AB (SE) | 2001-07-24 | — | — | US | disclosed |
| EP-0971920-A1 | COMPOUNDS FOR INHIBITION OF GASTRIC ACID SECRETION | Astra Aktiebolag (SE) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998037080-A1 | COMPOUNDS FOR INHIBITION OF GASTRIC ACID SECRETION | ASTRA AKTIEBOLAG (SE) | 1998-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170057954-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE | AADAC, PAICS, TNNI3 | SMN1; SMN2 1719/4885MAPK1 1632/4885MAPT 4728/4885 |
| US-20170217954-A1 | CYANO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE | AADAC, TNNI3, PCCA | SMN1; SMN2 1642/4885MAPK1 1444/4885MAPT 4789/4885 |
| US-20140128386-A1 | Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use | AADAC, TNNI3, PAH | SMN1; SMN2 1547/4885MAPK1 1907/4885MAPT 4732/4885 |
| US-20140128424-A1 | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use | TNNI3, AADAC, TNNT2 | SMN1; SMN2 1511/4885MAPK1 1803/4885MAPT 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.